Posted on March 07, 2018
In conjunction with the Conference on Retroviruses and Opportunistic Infections (CROI 2018), WHO organised an HIV/TB Research Frontiers meeting entitled "Short-Course Rifamycin Regimens and Dolutegravir: Silver Bullets?" on March 4, 2018. The meeting was chaired by Richard Chaisson of Johns Hopkins Medicine, and Constance Benson of the University of California, San Diego. The main aim of the meeting was to stimulate high level scientific debate around the opportunities, challenges, and scientific research implications posed by the latest short-course rifamycin-based TB preventive regimens in the context of the latest generation of antiretroviral drugs such as Dolutegravir. This was followed by a round table meeting to identify critical research and implementation priorities to cut and eliminate TB deaths among people living with HIV in the context of differentiated delivery of the HIV cascade of care. For more details on both these meetings and on coverage of HIV-associated TB at the CROI conference itself, please see the link below.